Last reviewed · How we verify

A Double-Blind, Parallel-Group Study of the Safety, Tolerability and Immunogenicity of a Range of Doses and Dosing Schedules of Recombinant (rPA Based) Anthrax Vaccine in Healthy Subjects

NCT00170456 Phase 2 COMPLETED

This is a dose ranging study comparing different vaccine schedules of rPA vaccine for anthrax. Safety and the capability to induce an immune response will be evaluated.

Details

Lead sponsorPharmAthene UK Limited
PhasePhase 2
StatusCOMPLETED
Enrolment415
Start date2005-03
Completion2007-02

Conditions

Interventions

Primary outcomes

Countries

United Kingdom